MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bright Minds Biosciences Inc (CSE:DRUG)

109.41 -5.28 (-4.60%)
Streaming Delayed Price Updated: 3:46 PM EDT, Aug 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 600
Open 110.87
Bid (Size) 105.31 (200)
Ask (Size) 125.00 (100)
Prev. Close 114.69
Today's Range 108.63 - 114.78
52wk Range 53.99 - 170.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Bright Minds Biosciences Announces Closing of US$175 Million Public Offering
From Bright Minds Biosciences
Via GlobeNewswire

Performance

YTD
-5.5%
-5.5%
1 Month
+4.8%
+4.8%
3 Month
-2.2%
-2.2%
6 Month
-1.9%
-1.9%
1 Year
+86.8%
+86.8%

More News

Read More
News headline image
Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Bright Minds Biosciences to Participate at Three Healthcare Conferences in March
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th
From Bright Minds Biosciences
Via GlobeNewswire
News headline image
New Study Reveals Psychedelic Drugs Can Be Almost as Life-Changing as Near-Death Experiences
Via PressReach
Topics Supply Chain
New Study Reveals Psychedelic Drugs Can Be Almost as Life-Changing as Near-Death Experiences
Via FinancialNewsMedia

Frequently Asked Questions

Is Bright Minds Biosciences Inc publicly traded?
Yes, Bright Minds Biosciences Inc is publicly traded.
What exchange does Bright Minds Biosciences Inc trade on?
Bright Minds Biosciences Inc trades on the Canadian Securities Exchange
What is the ticker symbol for Bright Minds Biosciences Inc?
The ticker symbol for Bright Minds Biosciences Inc is DRUG on the Canadian Securities Exchange
What is the current price of Bright Minds Biosciences Inc?
The current price of Bright Minds Biosciences Inc is 109.41
When was Bright Minds Biosciences Inc last traded?
The last trade of Bright Minds Biosciences Inc was at 08/20/26 03:46 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story